Overview

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.
Phase:
Phase 4
Details
Lead Sponsor:
PETHEMA Foundation
Treatments:
6-Mercaptopurine
Asparaginase
Daunorubicin
Mercaptopurine
Prednisone
Vincristine